How to Buy Zenas Biopharma Stock
Zenas Biopharma Inc
Zenas BioPharma, Inc. , a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies.
Zenas Biopharma stock last closed at $17.55, down 2.55% from the previous day, and has increased 56.7% in one year. It has overperformed other stocks in the Biotechnology industry by 0.68 percentage points. Zenas Biopharma stock is currently +106.23% from its 52-week low of $8.51, and -60.65% from its 52-week high of $44.60.
At the moment, there are 57.36M ZBIO shares outstanding. The market cap of ZBIO is $1.01B. In the past 24 hours, 466,000 ZBIO shares were traded.
How to Buy Zenas Biopharma Stock
Not sure how to invest in Zenas Biopharma stock? Here's how.
- Choose where to buy Zenas Biopharma stock: You need to choose a stock brokerage, but don't worry - we've tried dozens of stock brokerages and apps to help you figure out where to buy Zenas Biopharma stock.
- Create a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
- Deposit funds into your investment account: Choose your method of payment and add your info.
- Research Zenas Biopharma stock: The Zenas Biopharma ticker symbol is ZBIO. Is Zenas Biopharma stock a good investment? Should you buy shares of ZBIO? How do ZBIO's underlying business fundamentals look? Do top analysts think Zenas Biopharma is a good buy? Why has ZBIO's stock price moved recently? (Hint: Our stock market analysis website can help you evaluate if ZBIO is a good stock to buy).
- Execute your ZBIO trade: Decide if you will purchase ZBIO shares at the current market price or use a limit order to purchase ZBIO shares at a specific price.
- Get key alerts regarding your ZBIO position: Create a watchlist to track your position in Zenas Biopharma stock.
Step 1: Choose where to buy Zenas Biopharma stock
You need a brokerage account in order to access the NASDAQ market and buy ZBIO stock.
Our preferred brokerage: eToro
We believe that eToro is the best brokerage. eToro gives you:
- You can invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
- Access to world markets: From Tech to Industrials, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's leading exchanges.
- Social investing: eToro offers a community of more than 20 million users around the world. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of shares by creating an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Create a brokerage account
Now that you've chosen the best brokerage, you need to fill out some personal information so you can buy ZBIO today.
How to Start a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal data to start a new trading account.
- Submit your details by hitting the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your investment account
Now that you've opened your account on one of the most highly reviewed stock trading apps, you need to deposit funds:
Check out the video below to see the process of depositing funds into your new brokerage account.
Step 4: Research Zenas Biopharma stock
After you have identified the best place to buy Zenas Biopharma stock, it's very important to evaluate their stock prior to buying, so you truly understand the risk and upside.
Zenas Biopharma stock data
ZBIO Due Diligence Score
WallStreetZen was designed to help part-time investors do more in-depth fundamental analysis in less time.
You can view all of the due diligence checks on ZBIO's stock page.
How is ZBIO stock valued?
Investors use a variety of different financial metrics, analyses, models, and charts to gauge ZBIO's intrinsic value.
Using relative valuations methods:
- ZBIO could be undervalued based on its P/B ratio of 4.16x, relative to Biotechnology industry P/B ratio of 4.76x
You can access more valuation research on ZBIO's stock here.
A look at ZBIO Cashflows and Balance Sheet
Passed Financial Due Diligence Checks:
- There are more short-term assets than long-term liabilities on the ZBIO balance sheet.
- ZBIO has cash burn of 172351000. It has sufficient cash and short-term investments to cover this for at least one year.
- There are more short-term assets than short-term liabilities on the ZBIO balance sheet.
Failed Financial Due Diligence Checks:
- ZBIO profit margin has gone down from -3,139.8% to -3,777.4% in the past year.
- ZBIO has a relatively high debt to equity ratio of 0.58.
- ZBIO has $343.19M in cash and short term investments. This is not enough to cover its annual cash burn of $172.35M.
Do Wall Street analysts think it's a good time to buy ZBIO stock
Out of 6 sell side analysts who track ZBIO, the consensus analyst rating on Zenas Biopharma is a Buy
Please keep in mind that analyst forecasts are not recommendations, nor are they investment advice.
Latest ZBIO Analyst Forecasts
Cory Kasimov, a top 18% analyst from Evercore ISI Group initiates coverage on ZBIO with a buy rating and announces their ZBIO price target of $55.00, on Nov 26, 2025.
You can dive deeper into what analysts are projecting on the Zenas Biopharma stock forecast page.
ZBIO Trading Indicators
ZBIO Revenue
Last year, ZBIO revenue was $10.00M. Over the past two year, ZBIO's revenue has increased by -55.28% per year. This was slower than the Biotechnology industry average of 27.44%.
Dive into ZBIO's earnings and revenue performance here.
Latest Insiders Trades at ZBIO
Over the last 12 months, executives and large shareholders at ZBIO have bought more shares than they have sold.
Leon O. Moulder Jr., Chief Executive Officer of ZBIO, was the latest ZBIO insider to buy. They bought $616,700.00 worth of ZBIO stock on Apr 29, 2026.
Dig into more about who owns ZBIO shares here.
Does ZBIO provide a stable income stream?
No, Zenas Biopharma doesn't provide an income stream by paying out dividends.
Get analysis from other traders
One of the biggest reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to find out what other community members have to say.
Step 5: Execute your ZBIO trade
You have two main types of orders:
- Market order: A market order is an order to buy or sell a security at the best available price.
Market orders are mostly the best for newer investors. - Limit order: A limit order lets you buy or sell a security at a specific price (or better).
If you want to make sure you're buying or selling at a particular dollar amount limit, place a limit order.
Press the Open button and eToro will place the order.
If you require more info about buying stocks on eToro, click the helpful video below:
Step 6: Get key alerts regarding your ZBIO position
Now that you own some ZBIO stock, you'll want to stay up-to-date on your new investment.
Start a watchlist to get notified of important updates regarding your ZBIO stock.
ZBIO Feed
How to Buy Stock in Zenas Biopharma
To reiterate, here are the 6 steps you need to take to buy Zenas Biopharma stock right now:
- Choose where to buy Zenas Biopharma stock
- Create a brokerage account
- Deposit funds into your investment account
- Research Zenas Biopharma stock
- Execute your ZBIO trade
- Get key alerts regarding your ZBIO position
If you need a brokerage account, eToro is our recommended option.
Get Started with eToro TodayIf you want to watch your new investment in Zenas Biopharma, add ZBIO to your watchlist below.
Other Articles You Might Like
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.